While the drop in Ultragenyx stock certainly provides a lower entry point for new investors, the more prudent choice right ...

Final results from the VALOR trial and its open-label extension demonstrated the clinical benefit of tofersen in adults with ...

As of Tuesday, December 30, Ultragenyx Pharmaceutical Inc.’s RARE share price has surged by 9.99%, which has investors questioning if this is right time to sell.

Sean Ryder, professor at UMass Chan Medical School, has written a book to delve the mysteries of ribonucleic acid as a tool to fight diseases. Messenger ribonucleic acid, or mRNA, is in the public ...

By broadening definition of success to include sustained low-level HBsAg with suppressed HBV DNA, we can recognize clinically ...

Ultragenyx Pharmaceutical (RARE) remains a Sell after its Phase 3 OI program failed to meet primary fracture reduction ...

This Research Topic invites high-impact research that advances nanotechnology-enabled antiviral interventions across the pipeline from molecular design to ...

The flipside of biophobia is called biophilia, an innate affinity for nature. Both of these terms stem from evolutionary ...

A well-regarded treatment for trauma, cognitive processing therapy, equips clients with tools to thrive beyond mere survival.

After two decades of surgeries, prescriptions, and debilitating symptoms, this mom discovered a treatment that significantly ...

Using GLP-1s or considering it? New global research reveals social and psychological consequences for everyday lives.